宫颈癌紫杉醇化疗耐药机制的研究进展

doi:10.20047/j.issn1673-7210.2023.33.07

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (559 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Cervical cancer is one of the most common malignant tumors of the female reproductive system. Although this is despite breakthroughs in early screening and prevention, the incidence and mortality rates of cervical cancer are still on the rise in developing countries. Paclitaxel is a first-line chemotherapy drug for the treatment of cervical cancer, and because it is easy to produce chemotherapy resistance, it seriously affects the therapeutic effect and prognosis of patients. Therefore, it is of great significance to understand the molecular mechanism of chemotherapy resistance. In this paper, the research progress on the mechanism of chemotherapy resistance of paclitaxel in cervical cancer was reviewed, in order to provide new ideas for overcoming chemotherapy resistance of cervical cancer.

Key words： Cervical cancer Paclitaxel Drug resistance Mechanism research

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Jianqing WANG Ming XU Shuiqing ZHANG Jingjing HE Yue▲ WU Yumei▲

Cite this article:

XU Jianqing WANG Ming XU Shuiqing ZHANG Jingjing HE Yue▲ WU Yumei▲. Research progress on the mechanism of drug resistance to paclitaxel chemotherapy in cervical cancer[J]. 中国医药导报, 2023, 20(33): 39-42,47.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.33.07 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I33/39

[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J for Clini，2018，68（6）：394-424.
[2] Kitagawa R，Katsumata N，Shibata T，et al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer：The Open-Label Randomized Phase Ⅲ Trial JCOG0505 [J]. J Clin Oncol，2015，33（19）：2129-2135.
[3] Mabuchi S，Morishige K，Enomoto T，et al. Carboplatin and paclitaxel as an initial treatment in patients with stage Ⅳb cervical cancer：a report of 7 cases and a review of the liter- ature [J]. J Gynecol Oncol，2010，21（2）：93-96.
[4] Moore DH，Blessing JA，McQuellon RP，et al. Phase Ⅲ study of cisplatin with or without paclitaxel in stage ⅣB，recurrent，or persistent squamous cell carcinoma of the cervix：a gyne- cologic oncology group study [J]. J Clin Oncol，2004，22（15）： 3113-3119.
[5] Schiff PB，Fant J，Horwitz SB. Promotion of microtubule asse- mbly in vitro by taxol [J]. Nature，1979，277（5698）：665-667.
[6] Kampan NC，Madondo MT，McNally OM，et al. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer [J]. BioMed Res Int，2015，2015：413076.
[7] Scribano CM，Wan J，Esbona K，et al. Chromosomal instability sensitizes patient breast tumors to multipolar divisions ind- uced by paclitaxel [J]. Sci Translation Med，2021，13（610）：eabd4811.
[8] Robey RW，Pluchino KM，Hall MD，et al. Revisiting the role of ABC transporters in multidrug-resistant cancer [J]. Nat Reviews Cancer，2018，18（7）：452-464.
[9] Liu J，Wang M，Zhang X，et al. CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway [J]. Tumour Biol，2016，37（2）：2673-2682.
[10] Zhu K，Chen L，Han X，et al. Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosen- sitivity to cisplatin in HeLa human cervical cancer cells [J]. Oncol Rep，2012，27（4）：1027-1034.
[11] Murahari M，Prakash KV，Peters GJ，et al. Acridone-pyrim- idine hybrids-design，synthesis，cytotoxicity studies in resis- tant and sensitive cancer cells and molecular docking studies [J]. Eur J Med Chem，2017，139：961-981.
[12] Sun R，Jiang B，Qi H，et al. SOX4 contributes to the progres- sion of cervical cancer and the resistance to the chemothe- rapeutic drug through ABCG2 [J]. Cell Death Dis，2015，6（11）：e1990.
[13] Chen Z，Ling K，Zhu Y，et al. Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters [J]. Gene，2020，759：145000.
[14] Du J，Li B，Fang Y，et al. Overexpression of Class Ⅲβ-tubu- lin，SoX2，and nuclear Survivin is predictive of taxane re- sistance in patients with stage Ⅲ ovarian epithelial cancer [J]. BMC Cancer，2015，15：536.
[15] Hayashi Y，Kuriyama H，Umezu H，et al. Class Ⅲ beta- tub- ulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non- small-cell lung cancer [J]. Int Med，2009，48（4）：203-208.
[16] Lebok P，■ztürk M，Heilenk?觟tter U，et al. High levels of class Ⅲβ-tubulin expression are associated with aggressive tumor features in breast cancer [J]. Oncol Letter，2016，11（3）：1987-1994.
[17] English DP，Roque DM，Santin AD. Class Ⅲ b-tubulin overexpression in gynecologic tumors：implications for the choice of microtubule targeted agents? [J]. Expert Rev Anti- cancer Ther，2013，13（1）：63-74.
[18] Ferrandina G，Martinelli E，Zannoni GF，et al. Expression of class Ⅲ beta tubulin in cervical cancer patients admi- nistered preoperative radiochemotherapy：correlation with response to treatment and clinical outcome [J]. Gynecol Oncol，2007，104（2）：326-330.
[19] Zwenger AO，Grosman G，Iturbe J，et al. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens [J]. Int J Biol Markers，2015，30（3）：e301-14.
[20] Shi X，Sun X. Regulation of paclitaxel activity by microtu- bule-associated proteins in cancer chemotherapy [J]. Cancer Chemother Pharmacol，2017，80（5）：909-917.
[21] Rouzier R，Rajan R，Wagner P，et al. Microtubule-associ- ated protein tau：a marker of paclitaxel sensitivity in breast cancer [J]. Proceedings of the Nat Acad Sci U S A，2005， 102（23）：8315-8320.
[22] Tanaka S，Nohara T，Iwamoto M，et al. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer [J]. Cancer Chemother Pharmacol，2009，64（2）：341-346.
[23] Gurler H，Yu Y，Choi J，et al. Three-dimensional collagen type Ⅰ matrix up-regulates nuclear isoforms of the micro- tubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma [J]. Int J Mol Sci，2015，16（2）：3419-3433.
[24] Bauer JA，Chakravarthy AB，Rosenbluth JM，et al. Identifi- cation of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation [J]. Clin Cancer Res，2010，16（2）：681-690.
[25] Corrà F，Agnoletto C，Minotti L，et al. The Network of Non- coding RNAs in Cancer Drug Resistance [J]. Front Oncol，2018，8：327.
[26] Ayers D，Vandesompele J. Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance [J]. Genes，2017，8（3）：95.
[27] Xu J，Ma X，Yang H，et al. MiR-509-3p Induces Apoptosis and Affects the Chemosensitivity of Cervical Cancer Cells by Targeting the RAC1/PAK1/LIMK1/Cofilin Pathway [J]. Chem Pharm Bull，2021，69（4）：325-332.
[28] Shen Y，Zhou J，Li Y，et al. miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT [J]. PLoS One，2014，9（10）：e109299.
[29] Fan Z，Cui H，Yu H，et al. MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression [J]. Oncogenesis，2016，5（2）：e197.
[30] Cham J，Venkateswaran AR，Bhangoo M. Targeting the PI3K- AKT-mTOR Pathway in Castration Resistant Prostate Can- cer：A Review Article [J]. Clin Genitourin Cancer，2021， 19（6）：563.e1-.e7.
[31] Jung SH，Choi YJ，Kim MS，et al. Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix [J]. Oncotarget，2015，6（6）：4385-4393.
[32] Bava SV，Puliyappadamba VT，Deepti A，et al. Sensitization of taxol-induced apoptosis by curcumin involves down- regulation of nuclear factor-kappaB and the serine/thr- eonine kinase Akt and is independent of tubulin polymer- ization [J]. J Biol Chem，2005，280（8）：6301-6308.
[33] Liu JJ，Ho JY，Lee HW，et al. Inhibition of Phosphatidylino- sitol 3-kinase （PI3K） Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel- Mediated Resistance in Cervical Cancer [J]. Int J Mol Sci，2019，20（14）：3383.
[34] Majumder S，Crabtree JS，Golde TE，et al. Targeting Notch in oncology：the path forward [J]. Nat Rev Drug discov，2021， 20（2）：125-144.
[35] Yu L，Li W. Abnormal activation of notch 1 signaling causes apoptosis resistance in cervical cancer [J]. Int J Clin Exp Pathol，2022，15（1）：11-19.
[36] Wang L，Dai G，Yang J，et al. Cervical Cancer Cell Growth，Drug Resistance，and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097 [J]. Med Sci Monit，2018，24：4046-4053.
[37] Sun T，Zhang D，Wang Z，et al. Inhibition of the notch sign- aling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesen- chymal transition process [J]. Environ Toxicol，2021，36（9）：1758-1764.
[38] Shen CJ，Cheng YM，et al. LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresist- ance in cervical cancer cells [J]. J Drug Target，2017，25（7）： 637-644.
[39] Li J，Chen Q，Deng Z，et al. KRT17 confers paclitaxel-indu- ced resistance and migration to cervical cancer cells [J]. Life Sci，2019，224：255-262.
[40] Wang Y，Shen F，Zhou J，et al. Overexpression of ARHI increases the sensitivity of cervical cancer cells to paclitaxel through inducing apoptosis and autophagy [J]. Drug Dev Res，2022，83（1）：142-149.
[41] Peng X，Gong F，Chen Y，et al. Autophagy promotes paclit- axel resistance of cervical cancer cells：involvement of Warburg effect activated hypoxia-induced factor 1-α me- diated signaling [J]. Cell death Dis，2014，5（8）：e1367.